Diagnosticos da America (BSP:DASA3) Research & Development: R$0 Mil (TTM As of Mar. 2026)


BSP:DASA3 Diagnosticos da America SA BSP:DASA3
46 GF Score
Price R$2.78
GF Value R$1.70
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Diagnosticos da America Research & Development?

Diagnosticos da America BSP:DASA3 -1.42% 46 Research & Development is R$0 Mil as of Mar. 2026. GuruFocus rates BSP:DASA3 with a GF Score™ of 46/100 and a GF Value™ of R$1.70 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Diagnosticos da America's Research & Development for the three months ended in Mar. 2026 was R$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was R$0 Mil.

Diagnosticos da America  (BSP:DASA3) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Diagnosticos da America Research & Development Related Terms

Diagnosticos da America Research & Development Historical Data

* Premium members only.

The historical data trend for Diagnosticos da America's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diagnosticos da America Research & Development Chart

Diagnosticos da America Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Diagnosticos da America Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSP:DASA3
46GF Score
Diagnosticos da America SA BSP:DASA3
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diagnosticos da America Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of R$0 Mil mean?
Diagnosticos da America (BSP:DASA3) has a Research & Development of R$0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Diagnosticos da America and its competitors.
Is Diagnosticos da America's Research & Development too high?
Diagnosticos da America's current Research & Development is R$0 Mil. Overall, Diagnosticos da America has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnosticos da America's Research & Development compare to TMO and DHR?
Diagnosticos da America's Research & Development of R$0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Diagnosticos da America and its competitors. Diagnosticos da America's current Research & Development is R$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnosticos da America stock overvalued right now?
Based on GuruFocus' analysis, Diagnosticos da America (BSP:DASA3) is currently considered Significantly Overvalued. The stock's GF Value™ is R$1.70, compared to a current price of R$2.78 — trading 63.5% above its estimated fair value. The current Research & Development is R$0 Mil. Diagnosticos da America's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Diagnosticos da America (BSP:DASA3), the current Research & Development is R$0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diagnosticos da America (BSP:DASA3) Overvalued in 2026?

Based on GuruFocus' analysis, Diagnosticos da America stock appears to be overvalued. The current stock price of R$2.78 is trading 63.5% above its estimated GF Value™ of R$1.70. GuruFocus considers Diagnosticos da America to be Significantly Overvalued.

Key valuation signals for BSP:DASA3:

  • Research & Development: R$0 Mil
  • GF Value™: R$1.70 vs. price of R$2.78 (63.5% above fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the BSP:DASA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diagnosticos da America Business Description

Address Avenida Jurua, 434, Alphaville, Barueri, SP, BRA, 06455-010
Diagnosticos da America SA operates as a medical diagnostics company in Brazil. The company offers clinical analysis, diagnostic imaging tests, and patient service centers. It has three operating segments. Outpatient care services and care coordination includes Diagnosis and health management, Hospitals and oncology include Medical and hospital services & Foreign operations include Diagnosis. The majority is from the Hospitals and oncology segment. Geographically, it operates in Brazil and South America (Argentina, Uruguay, Chile and Colombia).
46GF Score

Get the complete analysis for BSP:DASA3

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$2.78
Price
R$1.70
GF Value